1. North-western State Medical University named after I. I. Mechnikov (St. Petersburg, Russian Federation)
2. Children’s Scientific Clinical Center of Infectious Diseases of Federal Medical Biological Agency (St. Petersburg, Russian Federation)
3. Pokrovsky Bank of Stem Cells (St. Petersburg, Russian Federation)
4. Institute of Cytology RAS (St. Petersburg, Russian Federation)

Keywords:liver cirrhosis,cell therapy,autologous mesenchymal stem cells,imaging cells in the human body

Abstract:The article provides our own observation of the use of autologous mesenchymal stem cells for the treatment of a patient with cirrhosis of the liver. In this observation, the possibility of visualization in the human body of the introduced autologous mesenchymal stem cells is presented. Changes in biochemical blood parameters are also presented one month after the introduction of cellular structures into the arterial bed of the liver.

• References total 6 ⇓ :: .
  1. Ludwig J., Viggiano T. R. Non–alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin Proc. 1980, 55:434–8.
  2. M. Carneiro de Moore. Nonalcoholic steatohepatitis // Clinical perspectives in gastroenterology, hepatology. – 2001. – № 2. – p. 12–15
  3. Fadeenko G. D. Fat liver: etiopathogenesis, diagnosis, treatment // Modern gastroenterology. 2003. – No. 3 (13). – pp. 9–17.
  4. Severov M. Non-alcoholic fatty liver disease / / Vrach. – 2002. – № 10. – p.23–26., 1212.
  5. Bellentani S, Tinbelli C. Epidemiology and risk factors for fatty liver. In: Leuschner U. James OFW, Dancygier H (eds.). Steatohepatitis (NASH and ASH), Kluwer Academic Publishers, Dordrecht 2001, 3–10.
  6. Kantarcıoğlu M, Demirci H, Avcu F, Karslıoğlu Y, Babayiğit MA, Karaman B, Öztürk K, Gürel H, Akdoğan Kayhan M, Kaçar S, Kubar A, Öksüzoğlu G, Ural AU, Bağcı S.: Efficacy of autologous mesenchymal stem cell transplantation in patients with liver cirrhosis. The Turkish J ournal of gastroenterology 2015 May;26(3):244–50.

Full text is published :
ASSESSMENT OF CHANGES IN BIOCHEMICAL BLOOD PARAMETERS IN A PATIENT DIAGNOSED WITH LIVER CIRRHOSIS, USING AUTOLOGOUS MESENCHYMAL STEM CELLS. Experimental and Clinical Gastroenterology Journal. 2018;150(02):174-176
Read & Download full text

1. S. M. Kirov Military Medical Academy the Russian Defense Ministry (St. Petersburg, Russian Federation)

Keywords:Drug-induced chronic liver disease,Idiosyncrasy,Levofloxacin,Ursodeoxycholic acid

Abstract:The presented clinical observation reflects the key issues of the drug-induced chronic liver disease (DICLD): the complexity of the interpretation of the cause-and-effect relationship. The drug-liver, the severity of the flow, the diagnostic concept, as an exclusion method, the lack of treatment standards and the difficulty of finding an effective therapy.

• References total 16 ⇓ :: .
  1. Болезни печени и желчевыводящих путей: Руководство для врачей/ Под ред. В. Т. Ивашкина. – М.: ООО «Издат. дом «М-Вести», 2002. – 416 с.
  2. Внутренние болезни. Печень, желчевыводящие пути, поджелудочная железа: учебное пособие /Г.Е. Ройтберг, А. В. Струтынский. – М.: МЕДпресс-информ, 2013. – 632 с.
  3. S. F. Galimova. Drug-induced liver injuries (Part 2). RJGHC. 2014. Vol.24. No1. P.21–28.
  4. Лекарственные поражения печени. Клинические рекомендации для врачей / Санкт-Петербургское общество гастроэнтерологов, гепатологов и диетологов. Райхельсон К. Л., Пальгова Л. К., Кондрашина Э. А., Марченко Н. В., Барановский А. Ю. – СПб., 2017. – 116 с.
  5. Хомерики С. Г. Холестаз: учебное пособие для врачей/ С. Г. Хомерики, Н. М. Хомерики. – М.: Прима Принт, 2014. – 52 с.
  6. Циммерман Я. С. Синдром холестаза (вопросы этиологии, патогенеза, классификации, диагностики и лечения): учебно-методическое пособие для врачей. – Пермь, 2005. – 38 с.
  7. Шерлок Ш., Дули Дж. Заболевания печени желчных путей: Пер. с англ. / Под ред. З. Г. Апросиной, Н. А. Мухина. – М.: Гэотар-Медицина, 1999. – 864 с.
  8. Björnsson E. S. Hepatotoxicity by Drugs: The Most Common Implicated Agents // Int J Mol Sci. – 2016. – Vol. 6; 17(2). – Р. E224.
  9. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. //World J Gastroenterol. – 2008. – Vol. 14(44). – Р. 6774–6785.
  10. Chen M., Suzuki A., Borlak J. et al. Drug-induced liver injury: Interactions between drug properties and host factors. //Journal of Hepatology. – 2015 – Vol.63. – P. 503–514.
  11. Chalasani N.P., Hayashi P.H, Bonkovsky H.L et al. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury // The American Journal of Gastroenterology. – 2014. –Vol. 109. –Р. 950–966.
  12. Rajesh K.G., Suzuki R., Maeda H. et al. Hydrophilic bile salt ursodeoxycholic acid protects myocardium against reperfusion injury in a PI3K. Akt dependent pathway // J. Mol. Cell. Cardiol. – 2005. – Vol. 39 (5). – P. 766–776.
  13. Stine J.G., Lewis J. H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review // Expert Rev GastroenterolHepatol. – 2016. – Vol. 10(4). – P. 517–536.
  14. Karlsen T.H., Lammert F., Thompson R. J. Genetics of liver disease: From pathophysiology to clinical practice. // Journal of Hepatology. – 2015. –Vol.62. –S.6-S.14
  15. Zimmerman H. J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals ОП the Liver. – New York, 1978. – Р. 349–369.
  16. http://livertox.nlm.nih.gov

Full text is published :
SEVERE DRUG-INDUCED CHRONIC LIVER DISEASE IN 30-YEAR-OLD PATIENT. Experimental and Clinical Gastroenterology Journal. 2018;150(02):177-182
Read & Download full text